The company is developing products with existing drug moieties, using a proprietary novel delivery system, to develop more effective treatments in areas of unmet medical need. The underlying technology, exclusively licensed and is being used to develop therapeutics for hormonal replacement therapy as well as for urothelial cell based carcinomas.
They have developed these through novel drug delivery system ("DDS") that enhances and reformulates proven drugs into more effective treatments. Its proliposomal technology overcomes formulation challenges of drugs that are poorly water-soluble, have low membrane permeability, high metabolism or systemic toxicity. DDS is highly modifiable and has been successfully applied to solid and liquid therapies.
The companies innovative oral drug delivery technology allows for drugs to be incorporated into a solid pro-liposomal formulation that is contained in an enteric coated capsule. The capsule bypasses gastric degradation in the stomach and solves the first pass metabolism challenge of some drugs. Once the capsule releases in the intestines and the formulation hydrates, the liposomal complexes are absorbed via the lymphatic system. By bypassing the liver, the platform has solved the challenge of hepatic metabolism and allows for excellent oral bio-availability of the drug.
All qualified applicants will receive consideration without regard to race, age, color, sex (including pregnancy), religion, national origin, disability, sexual orientation, gender identity, marital status, military status, genetic information, or any other status protected by applicable laws or regulations.
GPAC (Growing People and Companies) is an award-winning search firm specializing in placing quality professionals within multiple industries across the United States for the past 29 years. We are extremely competitive, client-focused and realize that our value is in our ability to deliver the right solutions at the right time.